Japanese pharmaceutical giant Takeda Pharmaceutical is evaluating the possibility of conducting global clinical trials in India. This move is considered strategic to accelerate the launch of new drugs in one of the world’s largest pharmaceutical markets. With its diverse patient population, cost-efficient research environment, and rapidly expanding medical infrastructure, India has become a key destination in Takeda’s global strategy.

According to Reuters, Annapurna Das, Head of India Operations at Takeda, stated that the company is still in the exploratory stage. While financial details have not yet been disclosed, Takeda reaffirmed its commitment to making India a central hub in its global operations (Reuters).

There are three main reasons why India is being prioritized:

• Diverse patient population, which makes clinical trials more representative.

• Cost efficiency, allowing research to be conducted with lower budgets.

• Expanding hospital network, enabling large-scale global trials.

Projections show that India’s clinical trial market will surpass USD 2 billion by 2030, making it highly attractive for multinational pharmaceutical companies like Takeda.

Takeda’s pipeline in India includes several priority products:

• A lung cancer drug set to be launched this year.

• A dengue vaccine developed in partnership with Indian company Biological E., currently awaiting regulatory approval.

In addition, Takeda is expanding research into gastrointestinal diseases, inflammation, and neuroscience, which are critical areas given the rising number of chronic disease patients in India.

Beyond clinical trials, Takeda is strengthening its digital foundation through the Innovation Centre in Bengaluru. This facility has grown rapidly, employing more than 750 experts in artificial intelligence, data science, engineering, and design.

The Innovation Centre plays a vital role in Takeda’s global digital transformation. By leveraging advanced data technologies, the company can accelerate trial analysis, reduce errors, and improve research accuracy.

Takeda is also opening doors to collaboration with local stakeholders in India. Universities, hospitals, and technology companies are seen as potential partners in building a robust R&D ecosystem. Through such partnerships, Takeda aims to provide Indian patients with faster access to innovative therapies.

This strategy also reflects a broader shift: multinational pharmaceutical companies are no longer focusing solely on traditional markets like Japan or the United States but are increasingly turning to South Asia as a hub of growth and innovation.

Takeda’s move aligns with a global trend in which India is emerging as a key destination for medical research. The country is attracting international pharmaceutical companies thanks to its ability to provide large, diverse, and representative clinical data.

If this strategy succeeds, Takeda will not only accelerate its product launches in India but also strengthen its competitive edge in the global market. This advantage could position the company ahead of rivals still relying on costly trials in developed nations.

Takeda’s plan to explore global clinical trials in India signals a significant shift in the international pharmaceutical landscape. India is no longer seen merely as a consumer market but as a center for medical research and innovation. With promising products such as its lung cancer drug and dengue vaccine, combined with digital capabilities at the Bengaluru Innovation Centre, Takeda is well-positioned to deliver faster medical breakthroughs that could benefit millions of patients.

Subscribe to get the latest posts sent to your email.

Type your email…

Subscribe

Takeda Pharmaceutical